Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-01-12
DOI
10.1002/ejhf.1708
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
- (2019) Darren K. McGuire et al. CIRCULATION
- Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes
- (2019) Subodh Verma et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2019 EXECUTIVE SUMMARY
- (2019) Alan J. Garber et al. Endocrine Practice
- Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program
- (2019) Gemma A. Figtree et al. CIRCULATION
- Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial
- (2019) Remo H. M. Furtado et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- The Serendipitous Story of SGLT2 Inhibitors in Heart Failure: New Insights from DECLARE-TIMI 58
- (2019) Subodh Verma et al. CIRCULATION
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
- (2019) Hsiang-Chun Lee et al. Cardiovascular Diabetology
- Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology
- (2019) Petar M. Seferovic et al. EUROPEAN JOURNAL OF HEART FAILURE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors
- (2019) George L. Bakris AMERICAN JOURNAL OF KIDNEY DISEASES
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics
- (2019) John J.V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
- (2019) Carol Pollock et al. Lancet Diabetes & Endocrinology
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
- (2018) Young-Gun Kim et al. Cardiovascular Diabetology
- The impact of diabetes on the prognostic value of left ventricular function following percutaneous coronary intervention: Insights from the British Cardiovascular Intervention Society
- (2018) Matthew Jackson et al. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes
- (2018) YASUHIRO MATSUBAYASHI et al. DIABETES
- Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction
- (2018) Rasmus Rørth et al. DIABETES CARE
- Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
- (2018) Mikhail Kosiborod et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
- (2018) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- SGLT2 inhibition and heart failure—current concepts
- (2018) Joaquim Silva Custodio et al. HEART FAILURE REVIEWS
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Effect of glucose-lowering therapies on heart failure
- (2018) Michael Nassif et al. Nature Reviews Cardiology
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- Risk of heart failure in a population with type 2 diabetes versus a population without diabetes with and without coronary heart disease
- (2018) Hua-Fen Chen et al. DIABETES OBESITY & METABOLISM
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
- (2018) Kim A. Connelly et al. Cell Metabolism
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease
- (2018) Hassan Khan et al. JOURNAL OF CARDIAC FAILURE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction
- (2018) Andrija Pavlović et al. European Journal of Preventive Cardiology
- The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors
- (2017) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis
- (2017) Xiaoling Cai et al. Obesity
- The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition
- (2017) Subodh Verma et al. JAMA Cardiology
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
- (2016) Hiroaki Kusaka et al. Cardiovascular Diabetology
- Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
- (2016) Kristy Iglay et al. CURRENT MEDICAL RESEARCH AND OPINION
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
- (2016) Isabelle Johansson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
- (2016) Matthew R. Weir POSTGRADUATE MEDICINE
- Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
- (2016) Darren K. McGuire et al. JAMA Cardiology
- Concomitant Diabetes Mellitus and Heart Failure
- (2015) Alessandra Dei Cas et al. CURRENT PROBLEMS IN CARDIOLOGY
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
- (2015) Richard E Gilbert et al. LANCET
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure
- (2015) Alessandra Dei Cas et al. JACC-Heart Failure
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Myocardial energetics in heart failure
- (2013) Alexander Nickel et al. BASIC RESEARCH IN CARDIOLOGY
- Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure
- (2013) Dean T. Eurich et al. Circulation-Heart Failure
- The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: Data from the SHORTWAVE study
- (2013) Giacomo Faden et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
- (2012) L. J. M. Boonman-de Winter et al. DIABETOLOGIA
- Diabetic cardiomyopathy: pathophysiology and clinical features
- (2012) Takayuki Miki et al. HEART FAILURE REVIEWS
- National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008
- (2011) Jersey Chen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
- (2009) Kevin M. Pantalone et al. ACTA DIABETOLOGICA
- Intensive glucose control and macrovascular outcomes in type 2 diabetes
- (2009) F. M. Turnbull et al. DIABETOLOGIA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now